Open access
Open access
Powered by Google Translator Translator

Nephrology

Systematic Review: Calcium channel blockers versus other classes of drugs for hypertension – “there is moderate certainty evidence that diuretics reduce major cardiovascular events and congestive heart failure more than CCBs”.

19 Oct, 2021 | 08:56h | UTC

Summary: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

Original Study: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

 

Commentary on Twitter

 

Urolithiasis: ED presentations, evaluation, management, and disposition.

19 Oct, 2021 | 08:53h | UTC

Urolithiasis: ED Presentations, Evaluation, Management, and Disposition – emDocs

 

Management of Diabetes Mellitus in patients with CKD: Core Curriculum 2022.

17 Oct, 2021 | 21:23h | UTC

Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022 – American Journal of Kidney Diseases

 

Home Hemodialysis: Core Curriculum 2021.

14 Oct, 2021 | 09:55h | UTC

Home Hemodialysis: Core Curriculum 2021 – American Journal of Kidney Diseases

 

Commentary on Twitter

 

Consensus Guidance: Hyperkalemia management in the emergency department.

13 Oct, 2021 | 01:34h | UTC

Hyperkalemia management in the emergency department: An expert panel consensus – Journal of the American College of Emergency Physicians Open

Related: Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more

Podcast: Hyperkalemia, Diet, K+ Binders, Exercise

Hyperkalemia: Pathophysiology, Risk Factors and Consequence

Hyperkalemia: Pathophysiology, Risk Factors and Consequence (several articles)

 

Study suggests a 30-second interval between automated office blood pressure measurements is as accurate and reliable as a 60-second interval.

8 Oct, 2021 | 10:09h | UTC

Impact of 30- Versus 60-Second Time Intervals Between Automated Office Blood Pressure Measurements on Measured Blood Pressure – Hypertension (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice.

7 Oct, 2021 | 10:17h | UTC

Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice – Nephrology Dialysis Transplantation

 

Commentary on Twitter

 

Long-Term Immunosuppression Management: Opportunities and Uncertainties.

7 Oct, 2021 | 10:15h | UTC

Long-Term Immunosuppression Management: Opportunities and Uncertainties – Clinical Journal of the American Society of Nephrology

 

Commentary on Twitter

 

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.

7 Oct, 2021 | 10:14h | UTC

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents – Kidney Research and Clinical Practice

 

Cohort study: Adding a new antihypertensive to existing regimens is associated with greater blood pressure reductions than maximizing dose.

6 Oct, 2021 | 09:57h | UTC

Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults: A Prospective Observational Study – Annals of Internal Medicine

News release: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine

Commentary: Adding an antihypertensive to existing regimens associated with greater BP reduction than maximizing dose, with some caveats in adherence – ACP Internist

Related: #ESCCongress – RCT: Initial hypertension treatment with a single pill with 4 drugs at quarter doses (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) achieved better BP lowering vs. standard monotherapy (irbesartan 150 mg).

 

Commentary on Twitter (thread – click for more)

 

Is salt good for you after all? The evidence says no.

6 Oct, 2021 | 08:52h | UTC

Is salt good for you after all? The evidence says no – The Conversation

Related:

#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.

Systematic Review: Altered dietary salt intake for people with chronic kidney disease.

New WHO benchmarks help countries reduce salt intake and save lives.

RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients

Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths

Meta-Analysis: Effect of Reduction in Dietary Sodium on Blood Pressure Levels

Cluster Randomized Trial: Effect of Salt Substitution on Community-wide Blood Pressure and Hypertension Incidence

 

Podcast: Urinary Stone Disease.

5 Oct, 2021 | 08:50h | UTC

#298 Urinary Stone Disease Will Rock Your World – The Curbsiders

 

Review: Membranous nephropathy.

1 Oct, 2021 | 10:01h | UTC

Membranous nephropathy – Nature Reviews Disease Primers (free for a limited period)

Infographic: Membranous nephropathy (free for a limited period)

 

Commentary on Twitter

 

Review: Monitoring of Treatment for Arterial Hypertension.

29 Sep, 2021 | 09:59h | UTC

Monitoring of Treatment for Arterial Hypertension – Deutsches Ärzteblatt International

 

Expert panel recommends against use of race in assessment of kidney function.

24 Sep, 2021 | 09:01h | UTC

Expert panel recommends against use of race in assessment of kidney function – STAT

Original Guidance: A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease – American Journal of Kidney Diseases

 

Commentary on Twitter

 

Landmark articles suggest eliminating race in the estimation of kidney function.

24 Sep, 2021 | 09:03h | UTC

Editorial: Time to Eliminate Health Care Disparities in the Estimation of Kidney Function – New England Journal of Medicine

Study 1: New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race – New England Journal of Medicine

Study 2: Race, Genetic Ancestry, and Estimating Kidney Function in CKD – New England Journal of Medicine

Commentaries:

NIH-supported study suggests alternative to race-based kidney function calculations – NIH News Releases

Remove Race From Equation Used to Assess Kidney Function, Researchers Say – AJMC

Researchers identify potential approach to eliminate race from equations to estimate kidney function – News Medical

 

Commentary on Twitter

 

KDIGO 2021 clinical practice guideline for the management of glomerular diseases.

21 Sep, 2021 | 09:05h | UTC

KDIGO 2021 clinical practice guideline for the management of glomerular diseases – Kidney Disease: Improving Global Outcomes

Executive summary: KDIGO 2021 Guideline for the Management of Glomerular Diseases – Kidney Disease: Improving Global Outcomes

 

Systematic Review: Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

16 Sep, 2021 | 09:53h | UTC

Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy – Cochrane Library

Summary: Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous kidney replacement therapy – Cochrane Library

 

Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study.

10 Sep, 2021 | 05:33h | UTC

Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study – The BMJ

Original study: Kidney Outcomes in Long COVID – Journal of the American Society of Nephrology

 

Long COVID and kidney disease.

10 Sep, 2021 | 05:31h | UTC

Long COVID and kidney disease – Nature Reviews Nephrology

 

NICE Guideline: Assessment and management of chronic kidney disease.

1 Sep, 2021 | 09:47h | UTC

Chronic kidney disease: assessment and management – National Institute for Health and Care Excellence

 

Study shows that current definitions of chronic kidney disease overestimate the CKD burden in older individuals and results in overdiagnosis.

1 Sep, 2021 | 09:43h | UTC

Accounting for Age in the Definition of Chronic Kidney Disease – JAMA Internal Medicine (free for a limited period)

Invited commentary: Overdiagnosis of Chronic Kidney Disease in Older Adults—An Inconvenient Truth – JAMA Internal Medicine (free for a limited period)

 

Commentary on Twitter

 

#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.

29 Aug, 2021 | 19:21h | UTC

Effect of Salt Substitution on Cardiovascular Events and Death – New England Journal of Medicine (link to abstract – $ for full-text)

News release: Low-sodium salt prevents stroke – European Society of Cardiology

Commentary: Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD – TCTMD

 

Commentary on Twitter

 

#ESCCongress – RCT: Finerenone reduced CV events in patients with kidney disease and type 2 diabetes (12.4% vs. 14.2% during a median follow-up of 3.4 years), but the risk of hyperkalemia was increased (10.8% vs. 5.3%).

29 Aug, 2021 | 18:14h | UTC

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes – New England Journal of Medicine

News release: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology

Commentaries:

Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease – FIGARO-DKD – American College of Cardiology

FIGARO-DKD and FIDELITY Findings Show Benefits of Finerenone to Improve Outcomes in Patients With Kidney Disease, Diabetes – American College of Cardiology

Related:

[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes

 

Commentary on Twitter

 

#ESCCongress – RCT: Initial hypertension treatment with a single pill with 4 drugs at quarter doses (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) achieved better BP lowering vs. standard monotherapy (irbesartan 150 mg).

29 Aug, 2021 | 18:11h | UTC

Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Quadruple UltrA-low-dose tReaTment for hypErTension – QUARTET – American College of Cardiology

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.